COMPOSITION:

Each film-coated tablet contains: Venetoclax … 100mg

INDICATION:  

LuciVenet is a BCL-2 inhibitor indicated:

· For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

· In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

DOSAGE AND USE:

5-week ramp-up dosing schedule

Week 1: LuciVenet 20mg once daily

Week 2: LuciVenet 50mg once daily

Week 3: LuciVenet 100mg once daily

Week 4: LuciVenet 200mg once daily

Week 5: LuciVenet 400mg once daily

The recommended dosage of LuciVenet is 400 mg once daily after completion of the 5-week ramp-up dosing schedule. Continue LuciVenet until disease progression or unacceptable toxicity.

Tablet should be swallowed whole & not chewed or crushed.

STORAGE:

in a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY: 

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of the reach of Children. Do not administered LuciVenet in Pregnancy and Lactation patient treatment.